TANGO THERAPEUTICS INC (TNGX)
US87583X1090 - Common Stock
First Week of September 20th Options Trading For Tango Therapeutics (TNGX)
Notable Two Hundred Day Moving Average Cross - TNGX
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Tango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
TNGX Crosses Above Key Moving Average Level
Tango Therapeutics (TNGX) Shares Cross Above 200 DMA
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Commit To Buy Tango Therapeutics At $5, Earn 21.7% Annualized Using Options
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
Tango Therapeutics Announces Discontinuation of TNG348 Program
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024
TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ:TNGX) just reported results for the first quarter of...
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
Oversold Conditions For Tango Therapeutics (TNGX)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Breaks Below 200-Day Moving Average - Notable for TNGX
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023
TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ:TNGX) just reported results for the fourth quarter o...
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
Tango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Pancreatic Cancer Treatments Poised for Major Advances in 2024
/PRNewswire/ -- USA News Group - One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly...
Commit To Buy Tango Therapeutics At $12.50, Earn 71.6% Annualized Using Options
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering...
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers – BOSTON, Mass., Nov. 13,...
Tango Therapeutics GAAP EPS of -$0.23, revenue of $10.7M
Tango Therapeutics press release (NASDAQ:TNGX): Q3 GAAP EPS of -$0.23.Revenue of $10.7M.
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose...